The Cardioprotective Effects of Irbesartan and Candesartan in Isoproterenol Induced Cardiomyopathy in Rats
Keywords:
angiotensin, isoproterenol, cardiomyopathy, ARBs, MMP-9, cTn-i, candesartan, irbesartan
Abstract
The presence of a wide selection of angiotensin receptor blockers and the conflicting evidence regarding their cardioprotective effect, led to the attempt to evaluate the impact of irbesartan and candesartan on cardiac hypertrophy and remodeling. Female Albino rats were divided into 3 groups. The first group served as the control group and was given 1 ml distilled water via oral gavage and 0.5 ml distilled water subcutaneously. The second group was the isoproterenol (ISO) group and was given a daily S.C. injection of ISO at a dose of 5 mg/kg. The third group served as the treatment group and it was subdivided into 2 groups, both received ISO as stated previously along with a treatment drug which was administered via oral gavage and they included: ISO-Irb(irbesartan 50 mg/kg/day), and ISO-Cand(candesartan 2.6 mg/kg/day). All groups were treated for a period of 14 days. The assayed parameters included; mean serum Matrix metalloproteinase 9 (MMP-9), Cardiac troponin I (cTn-I), and Heart weight to Body weight (Hw/Bw) ratio.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
Babuin L, Jaffe A.S (2005) Troponin: the biomarker of choice for the detection of cardiac injury. 173(10), 1191-1202.
M. Boluyt, X. Long, T. Eschenhagen, U. Mende, W. Schmitz, M. Crow, E. Lakatta (1995) Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart.
Sally Brady, Malcolm York, Cheryl Scudamore, Thomas Williams, William Griffiths, John Turton (2010) Cardiac Troponin I in Isoproterenol-Induced Cardiac Injury in the Hanover Wistar Rat: Studies on Low Dose Levels and Routes of Administration. 38(2), 287-291. https://doi.org/10.1177/0192623309357948
A. Burke (2011) Dilated Cardiomyopathy Pathology, Burke A.
Michel Burnier (2001) Angiotensin II Type 1 Receptor Blockers. 103(6), 904-912. https://doi.org/10.1161/01.cir.103.6.904
Cheng Y.S, Dai D.Z, Dai Y (2009) Isoproterenol disperses distribution of NADPH oxidase, MMP-9, and pPKCƐ in the heart, which are mitigated by endothelin receptor antagonist CPU0213, Acta Pharmcol. 30(8), 1099-1106.
Chowdhury D, Tangutur A.D, Saxena Khatua T.N, Banerjee S.K, Bhadra M.P (2013) A proteomic view of isoproterenol induced cardiac hypertrophy: Prohibitin identified as a potential biomarker in rats. 11(Issue1), 1-13.
Deschamp A.M, Spinale F.G (2006) Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation. 69(3), 666-676.
Delisa Fairweather, Eric D., Michael J. (2011) Biomarkers of Heart Failure in Myocarditis and Dilated Cardiomyopathy. 16, 323-348. https://doi.org/10.5772/19723
GopalD.M, Sam F (2013) New and emerging biomarkers in left ventricular systolic dysfunction-- insight into dilated cardiomyopathy, J. of Cardiovasc. Trans. 6, 516-527.
M. Gray, C. Long, J. Kalinyak, H. Li, J. Karliner (1998) Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-beta 1 and endotheline-1 from fibroblasts. 40(2), 352-63.
D. Grimm, D. Elsner, H. Schunkert, M. Pfeifer, D. Griese, G. Bruckschlegel, F. Muders, G. Riegger, E. Kromer (1998) Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system. 37(1), 91-100. https://doi.org/10.1016/s0008-6363(97)00212-5
Pamela Harvey, Leslie Leinwand (2011) Cellular mechanisms of cardiomyopathy. 194(3), 355-365. https://doi.org/10.1083/jcb.201101100
Heather L.C, Catchpole A.F, Stuckey D.J, Cole M.A, Carr C.A, Clarke K (2009) Isoproterenol induces in vivo functional and metabolic abnormalities; similar to those found in the infarcted rat heart. 60(3), 31-39.
Zhang Herman E.H, Rifai Lipshultz S.E, Takeda Chadwick D, Yu Z.X, Ferrans in (1999) Correlation Between Serum Levels of Cardiac Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by Doxorubicin. 17(7), 2237-2243.
Senbonmatsu Ichihara S, Ichiki Price E. Jr, Gaffney F.A, Inagami T (2001) Angiotensin II Type 2 Receptor Is Essential for Left Ventricular Hypertrophy and Cardiac Fibrosis in Chronic Angiotensin II-Induced Hypertension. 104(3), 346-351.
Shokei Kim, Hiroshi Iwao (2000) Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases. 52(1), 11-34. https://doi.org/10.1016/s0031-6997(24)01434-0
Kakuta H, Sudoh K, sasamata M, Yamagishi S (2005) Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers. 4(1), 41-46.
Lili Li, Yao Zhang, Yongli Li, Bo Yu, Yan Xu, Shidan Zhao, Zhenzhong Guan (2008) Mesenchymal stem cell transplantation attenuates cardiac fibrosis associated with isoproterenol-induced global heart failure. 21(12), 1181-1189. https://doi.org/10.1111/j.1432-2277.2008.00742.x
Maron B.J, Thiene Towbin J.A, Corrado Antzelevitch C, Arnett D, Moss A.J, Seidman C.E, Young J.B (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. 113(14), 1807-1816.
Charles McCartan, Robert Mason, S. Jayasinghe, Lyn Griffiths (2012) Cardiomyopathy Classification: Ongoing Debate in the Genomics Era. 2012, 1-10. https://doi.org/10.1155/2012/796926
Mehta P.K, Griendling K.K (2007) Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. 292(1), C82-C97.
G. Montalescot, H. Drexler, R. Gallo, T. Pearson, M. Thoenes, D. Bhatt (2009) Effect of Irbesartan and Enalapril in non-ST elevation acute coronary Syndrome: Results of the Randomized, double-blind ARCHIPELAGO study, Euro. 30(22), 2733-2741. https://doi.org/10.1093/eurheartj/ehp301
Diaz-Araya Ocaranza M.P, Muňoz Chiong M, Ebensperger Riveros J.P, Sabat S, Irarrẚzaval P, Jalil J.E, Lavandero S (2002) Isoproterenol and Angiotensin I-Converting Enzyme in Lung, Left Ventricle, and Plasma During Myocardial Hypertrophy and Fibrosis, J. Cardio. 40(2), 246-254. https://doi.org/10.1097/00005344-200208000-00010
Arivazhagan Palaniyappan, Richard Uwiera, Halliday Idikio, Bodh Jugdutt (2009) Comparison of vasopeptidase inhibitor omapatrilat and angiotensin receptor blocker candesartan on extracellular matrix, myeloperoxidase, cytokines, and ventricular remodeling during healing after reperfused myocardial infarction. 321(1-2), 9-22. https://doi.org/10.1007/s11010-008-9905-3
C. Richer, P. Fornes, C. Cazaubon, V. Domergue, D. Nisato, J. Giudicelli (1999) Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats. 41(1), 100-108. https://doi.org/10.1016/s0008-6363(98)00227-2
Marín Roldán V, Ruiz-Espejo Gimeno J.R, Feliu González J, Saura García-Honrubia A, Valdés Morena G, Vicente V (2008) Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. 156(1), 85-91. https://doi.org/10.1016/j.ahj.2008.01.035
Andrey Serra, Maria Higuchi, Silvia Ihara, Ednei Antônio, Marília Santos, Maria Bombig, Paulo Tucci (2008) Exercise training prevents β-adrenergic Hyperactivity-induced Myocardial Hypertrophy and Lesions, Euro. 10(6), 534-539. https://doi.org/10.1016/j.ejheart.2008.03.016
Watanabe Shirai K, Ma M, Inoue Wahed M.I, Saito Y, Kashimura Suresh P.S, Kodama Tachikawa H, Aizawa Y (2005) Effects of angiotensin-II receptor blocker candesartan cilexetil in rats with dilated cardiomyopathy. 269(1-2), 137-142.
Ulka Tipnis, Gui He, Suzhen Li, Gerald Campbell, Paul Boor (2000) Attenuation of isoproterenol-mediated myocardial injury in rat by an inhibitor of polyamine synthesis. 9(5), 273-280. https://doi.org/10.1016/s1054-8807(00)00038-7
Paolo Verdecchia, Fabio Angeli, Salvatore Repaci (2009) Comparative assessment of angiotensin receptor blockers in different clinical settings. 2009(5), 939-948.
Wexler R, Elton T, Pleister A, Feldman D (2009) Cardiomyopathy: An Overview. 79(9), 778-784.
Malcolm York, Cheryl Scudamore, Sally Brady, Christabelle Chen, Sharon Wilson, Mark Curtis, Gareth Evans, William Griffiths, Matthew Whayman, Thomas Williams, John Turton (2007) Characterization of Troponin Responses in Isoproterenol-Induced Cardiac Injury in the Hanover Wistar Rat. 35(4), 606-617. https://doi.org/10.1080/01926230701389316
Published
2014-09-25
Issue
Section
License
Copyright (c) 2014 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.